Our Science
At Full Circles, we envision a world free of autoimmune disorders and genetic diseases.
Enabled by 4 pathbreaking discoveries, we have devised a novel viral free gene editing platform that is capable of delivering payloads up to 20kb in size. Using our proprietary nuclease editors, we can achieve 6x more efficient genome integration in comparison to Cas9. Ultra-large therapeutic payload can be integrated in a safe and efficient way to address genetic root cause in a mutation agnostic manner.
Cargo
Delivery
Manufacturing
Modularity
Innovating from Scratch
C4DNA™
Circular • Clonal • Customizable • Clean
Our proprietary cssDNA benefits from the stability of circular DNA and a safety profile similar to mRNA. Owing to the absence of bacterial sequences or antibiotic markers, we are able to achieve unlimited payload integration with the smallest possible backbone sequence. These mini-circular single stranded DNA molecules are immune stealth.
Delivering the Message
Traditional CRISPR methods suffer from diffused concentrations of sgRNAs and edited gene sequences resulting in a lower integration efficiency.
We developed a novel enGager system to circumvent this issue.
Innovating from Scratch
C4DNA™
Innovating from Scratch
C4DNA™
A tripartite complex ensures that cssDNA is readily attached to the nuclease editor and results in 6x more efficient genome integration.
Scalable Integration
Using our GATALYST optimization approach, we have demonstrated the development of CAR-T cells for 60% cheaper and at a rate 80% faster than existing viral methods.
Our disease-agnostic approach ensures modularity and promotes scalable integration into your gene-editing goals - editing, replacing, or writing new genes.
Partner with us
Let’s join hands to achieve a world without genetic disorders.
We are looking to form strategic partnerships for cell engineering workflows and cell line development alongside rapid manufacturing of biologics, including CAR T cells and hematopoietic stem cells. Feel free to explore our current pipelines in development or reach out to talk with us about a new possibility. We can also license our technology to support your workflows.